Across TCGA pan-cancer cohorts, PTAR1 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated PTAR1 data layer compared with 25 for mass-spec protein and 1 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher PTAR1 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated PTAR1 expression acts as an unfavorable survival marker, although some lineages such as LSCC show a favorable association.

PDAC, LUAD, and LSCC are the cancer types where PTAR1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	All	0.671	0.909	.008	34	view →
LUAD	OS	Tertile	All	0.651	0.910	.005	12	view →
LSCC	DFS	Median	III,IV	1.000	0.524	.033	2	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: PTAR1 tumor-vs-normal RNA expression · all PTAR1 data types